Innovative Therapies Days 2024

9–12 Oct 2024 | BESANCON, France

MED'INN'Pharma

medinnpharma.com/Besançon, France
1 profile visit

About

MED’INN’Pharma (MIP) is a pre-clinical stage Biotech company founded in 2017 as a spin-off from the French blood bank establishment (EFS) and the French National Institute of Health (INSERM).

Our mission is to use our platform technology to develop a pipeline of disease modifying therapies derived from the secretomes of human cells. We are committed to develop drug candidates with durable efficacy by targeting the root cause of diseases. Our platform derived therapeutics can be tailored to several indications and delivery methods.

RESOLVIX, the lead candidate issued from our technology plateform, is dedicated to actively resolve, heal and regenerate pathologic inflammation in a wide range of degenerative diseases and conditions and with that intended to positively impacting human health span.

Representatives

Susanne Behlke

CSO

Med’Inn’Pharma